Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8029-8029
Author(s):  
Alexander E. Drilon ◽  
Lu Wang ◽  
Maria E. Arcila ◽  
Eun Jung Cho ◽  
Sohail Balasubramanian ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Next Generation ◽  
Genomic Alterations ◽  
Light Smoking ◽  
Lung Adenocarcinomas ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing

scholarly journals Clinical Application of Next Generation Sequencing in Recurrent Glioblastoma

2021 ◽  
Author(s):  
Daniel Zeitouni ◽  
Michael Catalino ◽  
Jordan Wise ◽  
Sean McCabe ◽  
Kathryn Pietrosimone ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Disease Control ◽  
Objective Response ◽  
Recurrent Glioblastoma ◽  
High Rate ◽  
Next Generation ◽  
Genomic Alterations ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing ◽  
Recurrent Gbm

BACKGROUND: Glioblastoma (GBM) is driven by various genomic alterations. Next generation sequencing (NGS) could yield targetable alterations that may impact outcomes. The goal of this study was to describe how NGS can inform targeted therapy (TT) in this patient population. METHODS: The medical records of patients (pts) with a diagnosis of GBM from 2017-2019 were reviewed. Records of patients with recurrent GBM and genomic alterations were evaluated. Objective response rates and disease control rates were deter-mined. RESULTS: A total of 87 pts with GBM underwent NGS. Forty percent (n = 35) were considered to have actionable alterations. Of the 35, 40% (n=14) pts had their treatment changed due to an alteration. The objective response rate (ORR) of this population was 43%. The disease control rate (DCR) was 100%. The absolute mean decrease in contrast enhancing disease was 50.7% (95% CI 34.8 – 66.6). CONCLUSION: NGS for GBM, particularly in the recurrent setting, yields a high rate of actionable alterations. We observed a high ORR and DCR, reflecting the value of NGS in deciding on TT to match alterations that are likely to respond. In conclusion, patient selection and availability of NGS may impact outcomes in select pts with recurrent GBM.

Next-generation sequencing (NGS) in advanced pancreatic adenocarcinoma (PA): A Brazilian experience.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 315-315
Author(s):  
Raphael Brandao Moreira ◽  
Matheus Bongers Alessandretti ◽  
Aline Da Rocha Lino ◽  
Rodnei Merlrina Martins Junior ◽  
Marcus Paulo Fernandes Amarante ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Pancreatic Adenocarcinoma ◽  
Mek Inhibitor ◽  
Next Generation ◽  
Genomic Alterations ◽  
Novel Therapy ◽  
Kras Mutations ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing ◽  
Advanced Pancreatic Adenocarcinoma

315 Background: Metastatic PA is a lethal malignancy with poor prognosis and limited therapeutic options. We hypothesized that a comprehensive next-generation sequencing (NGS) assay could identify novel therapy targets not routinely explored in PA patients. Methods: We included patients with advanced pancreatic adenocarcinoma (PA) with accessible lesion for biopsy. Paraffin-embedded tumor tissues were evaluated by the method of NGS (Foundation Medicine, Cambridge, MA, USA). Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to ≥ 50 ng of DNA extracted from 10 PA specimens and sequenced to high, uniform coverage. Genomic alterations (GAs), were characterized and reported for each patient sample. Actionable GAs were defined as those identifying anti-cancer targeted therapies either available on the market or in registered clinical trials. Results: A total of 10 PA patients were included. Median age was 56 years (range 31-79). All cases harbored at least one GA with a mean of 2.7 actionable GAs per tumor. The most common actionable GAs were KRAS (90%), PTCH1 (20%), STK11 (10%) and GNAS (10%). KRAS mutations potentially treatable with MEK-inhibitor were identified in 9 patients. However, none of them received a MEK-inhibitor. Activating STK11 point mutations not detectable by IHC/FISH, potentially targetable with m-Tor inhibitor therapies were identified in 1 patient, who received everolimus and had a long-lasting (> 6 months) partial response. Conclusions: NGS of PA was able to reveal genomic alterations that may be potentially responsive to available targeted therapy. We are just at the dawn of exploring this strategy and NGS can effectively contribute for increasing the understanding of the disease.

Sign in / Sign up

Export Citation Format

Share Document